Friday, September 25, 2015 12:23:58 PM
GLPG Call:
GLPG said very happy to get compound back unencumbered though acknowledging they were very surprised by decision. They were in contact with ABBV as late as yesterday without mention of this.
A couple notes from the call (going by memory and the connection was bad so take as is):
1. Notified by ABBV shortly before PR (CEO was looking up times on his computer but didn't catch so may have been simultaneous even)
2. On twitter I eluded to a comment in ABBV's PR about more certain path forward and when asked said only thing that could imagine is the male dosing issue (said to check with ABBV). Said GLPG strongly disagrees with this.
3. Had engaged 8 partners on non-confidential basis with public data. In coming weeks imagine will engage more and further some to confidentiality agreements.
4. CF partnership not affected.
5. Chrohn's program would be about 1 year ahead of ABBV's 494
6. Plan end of Phase 2 for filgotinib early '16. Phase 3 likely start after have partner input on design.
7. For Phase 3 dose thinking 12 weeks BID followed by QD dosing (didn't catch the dose)
8. Estimated $150 million for Phase 3 costs
Maybe a few other comments before/after the call on this guys stream
https://twitter.com/MauriceOnTW/with_replies
GLPG said very happy to get compound back unencumbered though acknowledging they were very surprised by decision. They were in contact with ABBV as late as yesterday without mention of this.
A couple notes from the call (going by memory and the connection was bad so take as is):
1. Notified by ABBV shortly before PR (CEO was looking up times on his computer but didn't catch so may have been simultaneous even)
2. On twitter I eluded to a comment in ABBV's PR about more certain path forward and when asked said only thing that could imagine is the male dosing issue (said to check with ABBV). Said GLPG strongly disagrees with this.
3. Had engaged 8 partners on non-confidential basis with public data. In coming weeks imagine will engage more and further some to confidentiality agreements.
4. CF partnership not affected.
5. Chrohn's program would be about 1 year ahead of ABBV's 494
6. Plan end of Phase 2 for filgotinib early '16. Phase 3 likely start after have partner input on design.
7. For Phase 3 dose thinking 12 weeks BID followed by QD dosing (didn't catch the dose)
8. Estimated $150 million for Phase 3 costs
Maybe a few other comments before/after the call on this guys stream
https://twitter.com/MauriceOnTW/with_replies
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
